Source comparison
Tesamorelin + Ipamorelin Blend GHRH + GHRP Synergy: Peptide Comparison
Before selecting a peptide combination, understanding how the tesamorelin + ipamorelin blend GHRH + GHRP synergy compares to alternative protocols clarifies why dual-pathway activation consistently outperforms single-agent approaches in growth hormone optimiza
This comparison does not assign a generated winner or score.
- Before selecting a peptide combination, understanding how the tesamorelin + ipamorelin blend GHRH + GHRP synergy compares to alternative protocols clarifies why dual-pathway activation consistently outperforms single-agent approaches in growth hormone optimization research.
- Tesamorelin (GHRH analog)
- GHRH receptor agonist. Direct somatotroph stimulation
- 3–5× baseline
- 90–120 minutes
- Highly selective for GH axis; no appetite, cortisol, or prolactin elevation
- Excellent for sustained moderate GH elevation but lacks peak amplitude without GHRP co-administration
- Ipamorelin (GHRP)
- Ghrelin receptor agonist. Suppresses somatostatin, amplifies GH pulse
- 2–3× baseline (alone)
- 60–90 minutes
- Most selective GHRP; minimal cortisol/prolactin effect
- Produces sharp GH peaks but tachyphylaxis risk with chronic solo use; benefits from GHRH synergy
- Tesamorelin + Ipamorelin Blend
- Dual-pathway: GHRH receptor + ghrelin receptor activation
- 5–8× baseline
- 120–180 minutes
- Combines selectivity of both; physiologic pulse replication
- Gold standard for body composition research. Peak amplitude, extended duration, minimal off-target effects
- Sermorelin (GHRH analog)
- GHRH receptor agonist
- 2–4× baseline
- Shorter half-life than tesamorelin; more frequent dosing required
- Effective but logistically inferior to tesamorelin due to stability and half-life constraints
- CJC-1295 + Ipamorelin
- GHRH analog (modified) + GHRP
- 4–6× baseline
- 90–120 minutes (DAC version: days)
- CJC-1295 DAC has prolonged half-life. Can cause supraphysiologic GH levels; No-DAC version closer to tesamorelin kinetics
- DAC version risks GH overexposure; No-DAC version comparable to tesamorelin + ipamorelin but less clinical data
- MK-677 (Ibutamoren)
- Oral ghrelin receptor agonist
- 2–4× baseline (chronic elevation)
- Continuous (24-hour half-life)
- Increases appetite, water retention, fasting glucose; not a peptide (small molecule mimetic)
- Convenient oral dosing but lacks pulsatility. Chronic GH elevation reduces receptor sensitivity over time